Praxis Precision Medicines (PRAX)
(Delayed Data from NSDQ)
$50.88 USD
+0.89 (1.78%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $50.89 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth D Momentum F VGM
Price, Consensus and EPS Surprise
PRAX 50.88 +0.89(1.78%)
Will PRAX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for PRAX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PRAX
JAZZ Falls as Suvecaltamide Tremor Study Fails to Meet Goals
Praxis Precision Medicines (PRAX) Surges 6.4%: Is This an Indication of Further Gains?
PRAX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Regenxbio (RGNX) Reports Q1 Loss, Lags Revenue Estimates
Agenus (AGEN) Reports Q1 Loss, Misses Revenue Estimates
Wall Street Analysts See a 144.74% Upside in Praxis Precision Medicines (PRAX): Can the Stock Really Move This High?
Other News for PRAX
Praxis Precision Medicines management to meet virtually with Piper Sandler
Praxis Precision Medicines management to meet virtually with Piper Sandler
Praxis Precision Medicines initiated with bullish view at Needham
Wall Street Analysts Are Bullish on Top Healthcare Picks
Value Of Praxis Precision Medicines' Lead Program In Essential Tremor Alone Is Underappreciated: Analyst